Drug comparisons
Rosiglitazone vs Troglitazone
Rosiglitazone vs Troglitazone: TZDs for type 2 diabetes. Troglitazone withdrawn due to liver failure. Rosiglitazone available with heart risks.
No comparison dimensions are available for this page.
Clinical context
This comparison is triggered when reviewing the safety history and market status of older thiazolidinedione drugs for type 2 diabetes.
Bottom line
Troglitazone is unavailable due to liver toxicity while Rosiglitazone is accessible yet limited by heart failure and ischemia risks, so neither is preferred.
All medication comparisons